Evidence map›Paper›PMID 36944981›Full record

ArticleOrphanet journal of rare diseases2023

GLUT1-DS Italian registry: past, present, and future: a useful tool for rare disorders.

Costanza Varesio, Valentina De Giorgis, Pierangelo Veggiotti, Nardo Nardocci, Tiziana Granata, Francesca Ragona, Ludovica Pasca, Martina Maria Mensi, Renato Borgatti, Sara Olivotto and 12 more

Full text readMulticenter Study
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Costanza VaresioDepartment of Child Neurology and Psychiatry, IRCCS Mondino Foundation (Member of ERN-Epicare), Pavia, Italy.
Valentina De GiorgisDepartment of Child Neurology and Psychiatry, IRCCS Mondino Foundation (Member of ERN-Epicare), Pavia, Italy. Valentina.degiorgis@mondino.it.ORCID 0000-0002-5828-7070
Pierangelo VeggiottiPediatric Neurology Unit, Vittore Buzzi Hospital, Milan, Italy.
Nardo NardocciDepartment of Pediatric Neuroscience Fondazione, IRCCS Istituto Neurologico Carlo Besta (Member of ERN-Epicare), Milan, Italy.
Tiziana GranataDepartment of Pediatric Neuroscience Fondazione, IRCCS Istituto Neurologico Carlo Besta (Member of ERN-Epicare), Milan, Italy.
Francesca RagonaDepartment of Pediatric Neuroscience Fondazione, IRCCS Istituto Neurologico Carlo Besta (Member of ERN-Epicare), Milan, Italy.
Ludovica PascaDepartment of Child Neurology and Psychiatry, IRCCS Mondino Foundation (Member of ERN-Epicare), Pavia, Italy.
Martina Maria MensiDepartment of Child Neurology and Psychiatry, IRCCS Mondino Foundation (Member of ERN-Epicare), Pavia, Italy.
Renato BorgattiDepartment of Child Neurology and Psychiatry, IRCCS Mondino Foundation (Member of ERN-Epicare), Pavia, Italy.
Sara OlivottoPediatric Neurology Unit, Vittore Buzzi Hospital, Milan, Italy.
Roberto PrevitaliDepartment of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Antonella RivaIRCCS Istituto Giannina Gaslini (Member of ERN-Epicare), Genoa, Italy.
Maria Margherita MancardiChild Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini (Member of ERN-Epicare), Genoa, Italy.
Pasquale StrianoIRCCS Istituto Giannina Gaslini (Member of ERN-Epicare), Genoa, Italy.
Mara CavallinNeuroscience Department, Meyer Children's University Hospital (Member of ERN-Epicare), Florence, Italy.
Renzo GuerriniNeuroscience Department, Meyer Children's University Hospital (Member of ERN-Epicare), Florence, Italy.
Francesca Felicia OpertoChild Neuropsychiatry Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Alice PizzolatoCloud R S.R.L., Milan, Italy.
Ruggero Di MauloCloud R S.R.L., Milan, Italy.
Fabiola MartinoAssociazione Italiana Glut1 aps, Milan, Italy.
Andrea LodiAssociazione Italiana Glut1 aps, Milan, Italy.
Carla MariniChild Neurology and Psychiatric Unit, Salesi Children's Hospital, Ancona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGLUT1 deficiency syndrome is a rare, genetically determined neurological disorder for which Ketogenic Dietary Treatment represents the gold standard and lifelong treatment. Patient registries are powerful tools providing insights and real-world data on rare diseases.

objectiveTo describe the implementation of a national web-based registry for GLUT1-DS.

methodsThis is a retrospective and prospective, multicenter, observational registry developed in collaboration with the Italian GLUT1-DS association and based on an innovative, flexible and configurable cloud computing technology platform, structured according to the most rigorous requirements for the management of patient's sensitive data. The Glut1 Registry collects baseline and follow-up data on the patient's demographics, history, symptoms, genotype, clinical, and instrumental evaluations and therapies.

resultsFive Centers in Italy joined the registry, and two more Centers are currently joining. In the first two years of running, data from 67 patients (40 females and 27 males) have been collected. Age at symptom onset was within the first year of life in most (40, 60%) patients. The diagnosis was formulated in infancy in almost half of the cases (34, 51%). Symptoms at onset were mainly paroxysmal (mostly epileptic seizure and paroxysmal ocular movement disorder) or mixed paroxysmal and fixed symptoms (mostly psychomotor delay). Most patients (53, 79%) are currently under Ketogenic dietary treatments.

conclusionsWe describe the principles behind the design, development, and deployment of the web-based nationwide GLUT1-DS registry. It represents a stepping stone towards a more comprehensive understanding of the disease from onset to adulthood. It also represents a virtuous model from a technical, legal, and organizational point of view, thus representing a possible paradigmatic example for other rare disease registry implementation.

Indexed as

Glucose Transporter Type 1Rare DiseasesFemaleHumansInfantItalyMaleProspective StudiesRegistriesRetrospective StudiesGlucose Transporter Type 1GLUT1 deficiency syndromePatient registryRare disease

Identifiers

PMID36944981
PMCPMC10029278

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read40
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.